FDA Pre-Submission (Q-Sub) Meeting Strategy: How to Get the Answers You Need Before You File

Stop Guessing. Start Asking.

One of the most costly mistakes medical device companies make is submitting a 510(k), De Novo, or PMA without first validating their regulatory strategy with FDA. The result is predictably painful: additional information requests, major deficiency letters, and clock stoppages that can add six to eighteen months to your timeline and hundreds of thousands of dollars to your burn rate.

There is a better path. FDA's Pre-Submission (Q-Sub) program — governed by the FDA guidance document "Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program" (updated January 2023) — gives sponsors a formal, documented mechanism to obtain agency feedback before committing resources to a full submission. Used correctly, a Q-Sub is one of the highest-leverage regulatory tools available to device developers at any stage.

What Is a Q-Sub, Exactly?

A Pre-Submission is a formal written request submitted to the relevant FDA Center (CDRH or CBER) asking for feedback on specific, well-defined questions related to your device submission strategy. Per the January 2023 Q-Sub guidance, FDA commits to providing written feedback within 70 calendar days of acknowledging the submission, and will hold a meeting (in-person, teleconference, or written-only) based on the complexity and nature of the request.

Q-Subs are not limited to pre-market submissions. They can be used to support:

• 510(k) predicate and substantial equivalence strategy
• De Novo classification requests and special controls framing
• PMA clinical study design and IDE strategy
• Biocompatibility and bench testing protocols (under ISO 10993 and applicable FDA guidance)
• Software as a Medical Device (SaMD) classification and predetermined change control plans
• Combination product designation requests
• Post-market study design under 21 CFR Part 822

Why Most Q-Subs Fail to Deliver Value

Here is the uncomfortable truth: a poorly constructed Q-Sub wastes your time, wastes FDA's time, and gives you answers that are either too vague to act on or, worse, misinterpreted. FDA reviewers respond to what you ask — not what you meant to ask. If your questions are broad, ambiguous, or structurally flawed, you will receive broad, non-committal answers.

The most common Q-Sub mistakes we see at ADB Consulting include:

• Asking yes/no questions instead of framing substantive regulatory questions — FDA will not simply say "your predicate is fine." Ask them specifically what evidence they would expect to support substantial equivalence for a given technological characteristic.
• Submitting without a clearly articulated device description — Reviewers cannot give you meaningful feedback on testing requirements or classification if they do not have a precise understanding of your device's intended use, indications for use, and technology.
• Failing to include a proposed regulatory pathway with supporting rationale — You are not asking FDA to do your regulatory strategy homework. You are asking them to respond to a reasoned position you have already developed.
• Not requesting a meeting when one is warranted — For complex devices, novel technologies, or first-of-a-kind indications, a written-only Q-Sub is often insufficient. Request a teleconference and prepare a focused meeting agenda.

A Practical Framework for High-Value Q-Sub Strategy

Step 1: Define Your Regulatory Hypothesis First

Before drafting a single question, your team must align internally on a proposed regulatory pathway, intended use statement, predicate strategy (if applicable), and a preliminary testing rationale. Your Q-Sub should present FDA with a developed position and ask them to affirm, modify, or challenge it.

Step 2: Write Narrow, Answerable Questions

Each question in your Q-Sub should be independently answerable, specific to a discrete regulatory issue, and tied to a defined decision point in your development program. Limit your submission to five to eight focused questions. More than that dilutes reviewer attention and often results in generalized responses.

Step 3: Anticipate FDA's Likely Concerns

Review the relevant FDA guidance documents, recognized consensus standards (accessible via FDA's Recognized Consensus Standards Database under 21 CFR Part 895), and any publicly available 510(k) summary or De Novo decision documents for similar devices. Understanding FDA's existing thinking on your device type gives you the context to ask smarter, more targeted questions.

Step 4: Prepare for the Meeting Strategically

If a meeting is granted, treat it as a formal regulatory negotiation, not a casual conversation. Prepare a slide deck that concisely summarizes your device, proposed pathway, and the specific decision points you need resolved. Designate a single spokesperson. Do not improvise answers to questions outside your preparation — it is entirely appropriate to say you will respond in writing.

Step 5: Document and Leverage the Written Feedback

FDA's written Q-Sub response is not legally binding, but it carries significant practical weight. Under 21 CFR 10.115 and FDA's own good guidance practices, this feedback reflects the agency's current thinking and will inform how your submission is reviewed. Incorporate it directly into your regulatory strategy documentation and submission cover letter.

The Strategic Bottom Line

A well-executed Q-Sub program compresses your regulatory timeline, reduces submission deficiency risk, and gives your development team the clarity needed to allocate resources efficiently. For startups preparing for a first submission, or established companies entering a new indication or technology category, a Q-Sub is not optional — it is foundational.

The question is not whether to use the Q-Sub program. The question is whether you have the regulatory expertise to use it effectively.

Work With a Regulatory Partner Who Knows the Process Cold

At ADB Consulting & CRO Inc., we help medical device companies design and execute Q-Sub strategies that produce actionable FDA feedback — not boilerplate responses. From drafting technically precise questions to preparing your team for the meeting itself, we bring the regulatory depth and FDA engagement experience your program needs to move faster and file smarter.

Book your free discovery call today at adbccro.com and let's map out your Q-Sub strategy before your next development milestone.